MetaVia said its global intellectual property portfolio for vanoglipel includes 48 granted and pending patents across three patent families. The company said the patents cover the compound, manufacturing methods, and pharmaceutical compositions. MetaVia said the portfolio includes the U.S., Europe, Japan, China and other countries, with protection into 2035 unless extended further. President and CEO Hyung Heon Kim commented on the company’s intellectual property strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY08098) on March 12, 2026, and is solely responsible for the information contained therein.
Comments